Ivabradine

Drug Profile

Ivabradine

Alternative Names: AMG-998; Coralan; Coraxan; Corlanor; Corlentor; Ivabradine hydrochloride; LANCORA; ONO-1162; Procoralan; S-16257; S-16257-2; S-57

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier
  • Developer Amgen; Ono Pharmaceutical; Servier; University of California, San Diego
  • Class Benzazepines; Bradycardic agents; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Hyperpolarisation activated cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris; Chronic heart failure
  • Phase III Coronary artery disease; Tachycardia
  • Phase II Low cardiac output

Most Recent Events

  • 31 Jul 2017 Servier terminates a phase-II trial in Healthy volunteers in United Kingdom (PO) (EudraCT2012-005627-32)
  • 20 Jun 2017 Phase-III clinical trials in Tachycardia (postural orthostatic tachycardia syndrome) in USA (PO) (NCT03182725)
  • 10 Jan 2017 Registered for Chronic heart failure in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top